<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Regulatory support on FinanClub</title>
    <link>https://finan.club/tags/regulatory-support/</link>
    <description>Recent content in Regulatory support on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 09 Feb 2024 09:04:23 +0000</lastBuildDate><atom:link href="https://finan.club/tags/regulatory-support/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>ARDX</title>
      <link>https://finan.club/us/ardx/</link>
      <pubDate>Fri, 09 Feb 2024 09:04:23 +0000</pubDate>
      
      <guid>https://finan.club/us/ardx/</guid>
      <description>score:47
Chances: Ardelyx (ARDX) has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects. The biotech market is projected to experience robust growth from 2024 to 2030, with an expanding clinical trial pipeline and strong regulatory support for startups.</description>
    </item>
    
  </channel>
</rss>
